| 5.44 0.03 (0.55%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.04 | 1-year : | 9.39 |
| Resists | First : | 6.88 | Second : | 8.04 |
| Pivot price | 4.88  |
|||
| Supports | First : | 4.77 |
Second : | 3.47 |
| MAs | MA(5) : | 5.69 |
MA(20) : | 4.65 |
| MA(100) : | 3.68 |
MA(250) : | 3.97 |
|
| MACD | MACD : | 0.4  |
Signal : | 0.4 |
| %K %D | K(14,3) : | 48.6 |
D(3) : | 58 |
| RSI | RSI(14): 64.6 |
|||
| 52-week | High : | 6.88 | Low : | 2.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRMD ] has closed below upper band by 29.6%. Bollinger Bands are 233% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.57 - 5.59 | 5.59 - 5.61 |
| Low: | 5.24 - 5.26 | 5.26 - 5.29 |
| Close: | 5.4 - 5.43 | 5.43 - 5.48 |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Mon, 08 Apr 2024
CorMedix (CRMD) Shows Strength: Stock Moves Up 35.8% - Yahoo Movies UK
Sat, 06 Apr 2024
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth - Simply Wall St
Tue, 02 Apr 2024
Breakeven On The Horizon For CorMedix Inc. (NASDAQ:CRMD) - Yahoo Finance
Wed, 13 Mar 2024
Earnings call: CorMedix outlines DefenCath launch and financials - Investing.com
Wed, 13 Mar 2024
Cormedix Inc.'s DefenCath Success Hinges on Two Major Dialysis Providers: A High-Stakes Gamble in Outpatient ... - TipRanks
Tue, 12 Mar 2024
CorMedix: Q4 Earnings Snapshot - Houston Chronicle
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 34.1 (%) |
| Shares Short | 8,250 (K) |
| Shares Short P.Month | 7,720 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.5 % |
| Return on Equity (ttm) | -74.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -5.98 |
| PEG Ratio | 0 |
| Price to Book value | 4.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|